RANBAXY... Constantly proving the world wrong with its path breaking innovations, this pharma biggie has really travelled far since its inception
Creativity
and innovation are two things that go hand in hand with the global pharmaceutical industry. But that’s not beentrue for Indian pharma, or at least that’s what the world thought till a few years back. While the industry long struggled to rid itself of the image that labelled its affiliates as trespassers of intellect; only few actually attempted to test their mettle against time. And Ranbaxy happens to be one such company. While growth through acquisition is one of Ranbaxy’s stated strategies, the enunciation has always been on delivering value through path-breaking studies and R&D. “R&D is one of Ranbaxy’s core strengths and fundamental to our growth. Our innovation capabilities have led to the delivery of a robust product pipeline,” a Ranbaxy spokesperson told 4Ps B&M. Well, the results are there for all to see. Ranbaxy, in 2006, landed itself on top position in patent filing list of companies from the developing nations. Being the first among its Indian peers to file for (Para IV) products last year, the company has attached the tag of a true Indian multinational to itself. It was one of the first Indian drug-maker to start a joint venture abroad, a strategy that has led it to such great heights. One of the biggest R&D spenders among Indian pharma biggies, with over 7% of its global revenues (much ahead of the industry average) being invested in R&D, Ranbaxy has emerged as an ingenious innovator in true sense!
For more articles, Click on IIPM Article
Source : IIPM Editorial, 2008
An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative
For More IIPM Info, Visit below mentioned IIPM articles.
IIPM - Admission Procedure
IIPM is A World of Career
Why Study Abroad When IIPM Gives You 3 global Advantages!
Creativity
and innovation are two things that go hand in hand with the global pharmaceutical industry. But that’s not beentrue for Indian pharma, or at least that’s what the world thought till a few years back. While the industry long struggled to rid itself of the image that labelled its affiliates as trespassers of intellect; only few actually attempted to test their mettle against time. And Ranbaxy happens to be one such company. While growth through acquisition is one of Ranbaxy’s stated strategies, the enunciation has always been on delivering value through path-breaking studies and R&D. “R&D is one of Ranbaxy’s core strengths and fundamental to our growth. Our innovation capabilities have led to the delivery of a robust product pipeline,” a Ranbaxy spokesperson told 4Ps B&M. Well, the results are there for all to see. Ranbaxy, in 2006, landed itself on top position in patent filing list of companies from the developing nations. Being the first among its Indian peers to file for (Para IV) products last year, the company has attached the tag of a true Indian multinational to itself. It was one of the first Indian drug-maker to start a joint venture abroad, a strategy that has led it to such great heights. One of the biggest R&D spenders among Indian pharma biggies, with over 7% of its global revenues (much ahead of the industry average) being invested in R&D, Ranbaxy has emerged as an ingenious innovator in true sense!For more articles, Click on IIPM Article
Source : IIPM Editorial, 2008
An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative
For More IIPM Info, Visit below mentioned IIPM articles.
IIPM - Admission Procedure
IIPM is A World of Career
Why Study Abroad When IIPM Gives You 3 global Advantages!
No comments:
Post a Comment